Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Leukemia, Myeloid, Acute 35Myelodysplastic Syndromes 33Multiple Myeloma 30Lymphoma, Non-Hodgkin 29Hodgkin Disease 28Graft vs Host Disease 26Leukemia, Lymphocytic, Chronic, B-Cell 25Lymphoma 24Leukemia 24Hematologic Neoplasms 20Neoplasms 18Lymphoma, Mantle-Cell 18Sarcoma 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Breast Neoplasms 17Tuberous Sclerosis 15Myeloproliferative Disorders 15Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Burkitt Lymphoma 14Waldenstrom Macroglobulinemia 13Lymphoma, B-Cell, Marginal Zone 13Recurrence 12Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 12Prostatic Neoplasms 11Primary Myelofibrosis 11Melanoma 11Leukemia, Myelomonocytic, Chronic 11

Interventions

Doxorubicin 17Ifosfamide 16Radiotherapy 10Filgrastim 5Imatinib Mesylate 4Etoposide 4Chemotherapy, Adjuvant 4pazopanib 3Vincristine 3Neoadjuvant Therapy 3Dactinomycin 3Cyclophosphamide 3Carboplatin 3pegfilgrastim 2cixutumumab 2brostallicin 2belinostat 2Trabectedin 2Sunitinib 2Radiotherapy, Conformal 2Radiation Dose Hypofractionation 2Epirubicin 2Diathermy 2temsirolimus 1soblidotin 1selinexor 1saracatinib 1romidepsin 1ribociclib 1reolysin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fibrosarcoma × Sirolimus × Clear all
NCT01614795 2018-12-11

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡